Small cell lung cancer (SCLC) remains one of the most lethal thoracic malignancies, characterized by rapid progression, early metastasis, and limited durable responses to conventional therapy. Delta-like ligand 3 (DLL3), a Notch pathway inhibitory ligand aberrantly overexpressed on the surface of approximately 70-85% o...
Vivian Tieu, Z. Arter, M. Nagasaka· Cancer Treatment Reviews· 0 citations
86
Background:
Major advances in HIV and cancer care have occurred over the past two decades, but whether outcomes for people living with HIV (PLHIV) with cancer have improved remains uncertain. We evaluated palliative care utilization, hospitalization burden, and survival across predefined calendar eras from 2...
K. A. Aldecoa, Chef Stan L. Macaraeg, Misako Nagasaka et al.· JCO Oncology Practice· 0 citations
This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.
X. Le, A. Passaro, Yuan-Yuan Zhao et al.· The Lancet Oncology· 0 citations
XPO1 inhibitor Eltanexor enhances the efficacy and durability of KRAS and pan-RAS inhibition in PDAC models and provides a preclinical rationale for clinically evaluating Eltanexor in combination with RAS-targeted therapies to delay or overcome adaptive resistance in KRAS-mutant PDAC.
H. Y. Khan, M. Al-Hallak, A. Aboukameel et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.